Introducing SERB Pharmaceuticals

SERB Pharmaceuticals equips healthcare providers worldwide with lifesaving medicines for patients facing rare diseases and emergencies.

Healthcare providers in over 100 countries rely on us for a broad range of essential medicines delivered via healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations.

Who we are

SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).

For over 30 years we have consistently supplied emergency medicines, medical countermeasures, and the world’s leading portfolio of antidotes. In this time, we have built trusted partnerships, integrated infrastructure and quality processes to get our medicines to patients with urgency.

Our proven ability to acquire, develop, manufacture, launch and commercialize specialist medicines allows us to meet critical medical needs.

Improving patients’ quality of life and offering hope is what motivates and inspires us.

Learn more about SERB

70+

Medicines

600+

Dedicated employees

Direct sales in

18

countries

Supplying

100+

countries

Latest news

  • 23 October 2026
    SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026 
    –       Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful –       Graft and patient survival were 92% and 98%, respectively  –       Idefirix® was generally well tolerated with a safety profile consistent with previous clinical trial experience –       SERB acquired the European and MENA rights to […]
    Read release
  • 25 August 2026
    SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
    Multidisciplinary panel publishes 30 consensus statements to improve communication and shared decision-making in neuroblastoma care WEST CONSHOHOCKEN:  SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that “Bridging the Gap: Establishing Consensus for Improving Neuroblastoma Diagnosis and Care Experiences for Patients and Caregivers” has been published in Pediatric […]
    Read release
  • 01 July 2026
    SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma 
    BRUSSELS, 1 July 2026: SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from […]
    Read release
See all news

Latest insight

  • Corporate
  • Responsibility

Marie Botin, Chief HR Officer

10 November 2026

What makes SERB special? A shared purpose, brought to life every day 

There is something particularly rewarding about seeing the company you know from the inside recognised by the wider life sciences community. SERB has been named a BioSpace 2027 Best Place to Work in the Small Employer category, on a list based on votes from over 9,000 life science community members.  For me, this recognition reflects […]

Read more
See all insights
You are leaving the SERB.com global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region